OA-14 Prospective Functional Bone Disease Evaluation of Newly Diagnosed Multiple Myeloma with Combined Use of (18)F-FDG-PET/CT and Whole-Body Diffusion Weighted Magnetic Resonance

IF 2.7 4区医学 Q2 HEMATOLOGY

Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2024-09-01 DOI:10.1016/S2152-2650(24)01855-X

Marco Talarico, Gabriella De Cicco, Paola Tacchetti, Lucia Pantani, Katia Mancuso, Ilaria Rizzello, Chiara Sartor, Miriam Iezza, Michele Puppi, Flavia Bigi, Ilaria Sacchetti, Enrica Manzato, Simone Masci, Roberta Restuccia, Simona Barbato, Vincenza Solli, Arrigo Cattabriga, Stefano Brocchi, Cristina Mosconi, Cristina Nanni, Elena Zamagni

引用次数: 0

查看原文本刊更多论文

OA-14 联合使用(18)F-FDG-PET/CT和全身弥散加权磁共振对新诊断的多发性骨髓瘤进行前瞻性骨病功能评估

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Lymphoma, Myeloma & Leukemia ONCOLOGY-HEMATOLOGY

CiteScore

2.70

自引率

3.70%

发文量

1606

审稿时长

26 days

期刊介绍： Clinical Lymphoma, Myeloma & Leukemia is a peer-reviewed monthly journal that publishes original articles describing various aspects of clinical and translational research of lymphoma, myeloma and leukemia. Clinical Lymphoma, Myeloma & Leukemia is devoted to articles on detection, diagnosis, prevention, and treatment of lymphoma, myeloma, leukemia and related disorders including macroglobulinemia, amyloidosis, and plasma-cell dyscrasias. The main emphasis is on recent scientific developments in all areas related to lymphoma, myeloma and leukemia. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.